valganciclovir hydrochloride 50 mg/mL

Valganciclovir, the active ingredient in valganciclovir hydrochloride 50 mg/mL, is an antiviral presented as a 50 mg/mL oral solution for oral use. It is used to treat cytomegalovirus (CMV) retinitis in patients with AIDS and to prevent CMV disease in transplant recipients. GNH USA supplies valganciclovir hydrochloride 50 mg/mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centers, and pharmacies worldwide.

GNH USA is a trusted global supplier of high-quality pharmaceuticals, ensuring that healthcare providers have access to essential medications for the treatment and prevention of serious infections.

Valganciclovir hydrochloride 50 mg/mL is an antiviral medication used to treat and prevent cytomegalovirus (CMV) infections.

- CMV retinitis in patients with AIDS: Treats an eye infection that can cause blindness. - Prevention of CMV disease in transplant patients: Used in kidney, heart, and kidney-pancreas transplant recipients at high risk of CMV disease. - Pediatric use: Prevents CMV disease in kidney and heart transplant patients aged 4 months to 16 years.

Valganciclovir hydrochloride 50 mg/mL can cause various side effects, ranging from common to serious.

Common Side Effects: - Nausea and vomiting. - Diarrhea. - Fever. - Headache. - Fatigue. - Decreased appetite. - Neutropenia (low white blood cell count). - Anemia (low red blood cell count).

Serious or Rare Side Effects: - Severe leukopenia (low white blood cell count). - Thrombocytopenia (low platelet count). - Bone marrow suppression. - Aplastic anemia. - Impairment of fertility. - Fetal toxicity. - Mutagenesis and carcinogenesis.

Valganciclovir hydrochloride 50 mg/mL should be used with caution and under medical supervision.

- Hematologic monitoring: Regular blood tests are required to monitor for leukopenia, neutropenia, anemia, and thrombocytopenia. - Renal function: Dose adjustment may be necessary in patients with renal impairment. - Pregnancy: Avoid use during pregnancy due to potential fetal toxicity. - Fertility: May cause temporary or permanent infertility in males and females. - Nephrotoxic drugs: Caution should be exercised when administering with other nephrotoxic drugs. - Store below 25°C: Keep in the original pack, protect from moisture.

Valganciclovir hydrochloride 50 mg/mL can interact with other medications, potentially affecting its efficacy or increasing the risk of side effects.

Major Interactions (Avoid): - Imipenem-cilastatin: Increased risk of seizures. - Zidovudine: Increased risk of neutropenia. - Mycophenolate mofetil: Increased risk of neutropenia. - Didanosine: Increased risk of pancreatitis. - Other nephrotoxic drugs: Increased risk of renal toxicity.

Moderate Interactions (Monitor Closely): - Probenecid: May increase valganciclovir levels. - Cimetidine: May increase valganciclovir levels. - Antacids: May decrease valganciclovir absorption. - Oral contraceptives: May decrease the effectiveness of oral contraceptives. - Other myelosuppressive drugs: Increased risk of bone marrow suppression.